ArticleScientific reports2026
Phytofabricated zinc oxide nanoparticles (ZnO-NPs) from a medicinal salt-tolerant Oxystelma esculentum (L.f.) Sm. extract and their multifunctional biological activities.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study accounts for the green synthesis of zinc oxide nanoparticles (ZnO-NPs) using Oxalis esculentum extract, aiming to evaluate their physicochemical properties and biomedical potential. The synthesized ZnO-NPs were characterized using UV–Vis spectroscopy, Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDX). XRD confirmed the hexagonal nanocrystalline nature of the ZnO-NPs, having a particle size of 13 nm, while FTIR indicated the existence of functional groups from plant phytochemicals. SEM revealed a quasi-spherical shape with agglomeration tendency, and EDX confirmed the presence of zinc (60.4%) and oxygen (22%) elements. The ZnO-NPs exhibited notable antifungal activity, with maximum inhibition rates of 72.3% against Aspergillus niger, 72.2% against Penicillium notatum, and 69.3% against Fusarium oxysporum at 4 mg/mL. Antibacterial activity against Escherichia coli peaked at a 13.9 mm inhibition zone at 8 mg/mL. The highest antileishmanial activity was 57.33% at 160 µg/mL, while hemolytic activity remained low at 1.41 ± 0.22% at 200 µg/mL, indicating biocompatibility. Additionally, the ZnO-NPs showed 79% anti-inflammatory activity at 800 µg/mL, 63.11 ± 0.22% alpha-amylase inhibition at 400 µg/mL, 17.66 ± 0.55% α-glucosidase inhibition at 400 µg/mL, and antioxidant activities, including 51.7 ± 1.2% TAC, 42.4 ± 0.02%TRP, and 55.6 ± 1.4%FRSA at 200 µg/mL of the NPs. In conclusion, the phyto-fabricated ZnO-NPs demonstrated significant antimicrobial, anti-inflammatory, antidiabetic, and antioxidant properties, highlighting their potential for future biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.